Minor elevated diabetes risk with statin use

Researchers reviewed safety data on seven statins from 135 studies published between 1985 and early this year, which included almost 250,000 patients.

Simvastatin and pravastatin had the best safety profile in the class, particularly when prescribed in low to moderate doses.

There was a 9% increased risk of diabetes and a 51% increased risk of transaminase elevations, particularly with higher doses of atorvastatin, fluvastatin, simvastatin as well as lovastatin, which is not registered in